Kyntra Bio, Inc. KYNB
4.32 USD -0.14 (-3.04%)
Nov 3, 2026, 3:32 PM EST
4.24 Day range 4.51
4.24 52-week range 11.39
- YTD
- -50.74%
- 1 year
- -60.72%
- Market cap
- 17.51M
- EPS (ttm)
- -7.64
- YTD return
- -50.74%
- 1-year return
- -60.72%
- Volume
- 18.16K
- Avg volume
- 21.84K
- Open
- 4.46
- Previous close
- 4.46
- Day's range
- 4.24 – 4.51
- 52-week range
- 4.24 – 11.39
YTD -4.89 (-53.38%)
Financials — quick view
KYNB Revenue — quarterly -1.47M
KYNB Net income — quarterly 11.97M
KYNB EPS — quarterly 2.96
News
Maxim Group Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $35 
Immatics (NASDAQ:IMTX) vs. Kyntra Bio (NASDAQ:KYNB) Financial Contrast 
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors 
Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41 
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference 
HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target - Kyntra Bio To Reduce The Maximum Aggregate Payments Under Its Royalty Financing Agreement From $125M To $65M; Co. Accelerated Payment Of $42.6M Upfront, Bringing Total Payments Made To Date To $50M; Remaining Payments, Capped At $15M, To Be Paid From 50% Of The Revenue Received From Astellas In The Astellas Territories Excluding Japan
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation 
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript 
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates
Your note
Sign in to keep a note on KYNB — it syncs with the Stock Master app.